Global Vaccines Market

The veterinary vaccines market consists of sales of vaccines and related services which are used for the treatment and prevention of diseases in animals. These veterinary vaccines reduce animal suffering and the transmission of microorganisms in the animal population. Veterinary vaccines are used to enhance the immunity power of animals by improving animal health, which also prevents the transmission of diseases from animals to humans. The various types of veterinary vaccines are live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine types. Inactivated vaccines differ from live but attenuated vaccines as they are made up of dead, or inactivated, viruses and bacteria. The disease types are anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, porcine reproductive and respiratory syndrome and the application areas include livestock vaccines, and companion animal vaccines. The global veterinary vaccines market size is expected to grow from $6.82 billion in 2021 to $7.38 billion in 2022 at a compound annual growth rate (CAGR) of 8.2%. The global veterinary vaccine market size is expected to grow to $9.47 billion in 2026 at a CAGR of 6.4%. The increase in the number of animals suffering from a range of diseases is increasing the demand for vaccines to prevent and treat such diseases, thus driving the veterinary vaccines market According to the estimates from a report by the Animal and Plant Health Agency, a total of 3289 number of new TB herd incidents were detected in England Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals causing a general state of illness, coughing and eventually lead to death. However, the disease can be treated with specific antibiotics that kill the TB bacteria. This rising prevalence of diseases in animals is expected to drive the veterinary vaccines market during the forecast period. High storage costs are acting as a major restraint for the growth of the veterinary vaccine market. Improper storage conditions and delays in shipping can cause vaccines to lose their desired immune properties. For example, during transportation, vaccines can undergo biodegradation, if they are not transported within the required temperature limits. Thus, special care is required for the transportation of the vaccines to maintain the efficiency of the vaccines, which increases the storage and transportation cost for the vaccines. According to a report published by the National Institute of Standards and Technology (NIST), approximately 35% of vaccines lost their potencies during the shipment, as they were stored at abnormal temperatures. Thus, high storage costs for vaccines are expected to result in additional costs for manufacturing companies and limit the growth of the market. Companies in the veterinary vaccines market are increasingly looking for strategic partnerships and collaborations to enter into new geographies and to share the Research & Development projects. For example, in 2020, the Pirbright Institute, a UK-based animal disease research institute, partnered with ECO Animal Health, a UK-based Pharmaceutical company, and the Vaccine Group (TVG) to develop porcine respiratory and reproductive syndrome virus (PRRSV) vaccines. The vaccine group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK. Similarly, MSD Animal Health, a division of Merck & Co with headquarters in the US, made a strategic partnership with Vinovo. This partnership will help MSD Animal Health to combine its unique broad vaccine product line and Vinovo’s vaccine delivery system to the vaccination process, thus improving bird welfare, and reducing vaccine reactions. Also, Wageningen bio veterinary research made a strategic alliance with Ceva with headquarters in Switzerland, to improve their Research on the global threat of emerging and reemerging diseases for animals. The veterinary vaccines market is regulated by authorities such as European Medical Agency and the US Center for Veterinary Biologics. For instance, veterinary vaccine companies in Europe are required to adhere to European technical requirements mentioned in Annex 1, Title II, to Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). According to these regulations, veterinary vaccines are required to undergo safety tests before getting approval, where vaccines are classified into activated vaccines and inactivated Vaccines. Inactivated vaccines, each batch of vaccines should have a dose that is double the standard dose. In inactivated vaccines, each batch of vaccines should be ten times the standard dose for the active vaccines. Activated vaccines are usually tested by in vitro titration, while serological tests are commonly used for inactivated vaccines. Major players in the veterinary vaccines market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), Ceva Santé Animale, Virbac, Biovac, Zoetis Animal Healthcare, and Hester Biosciences Ltd. North America was the largest region in the veterinary vaccines market in 2021. Asia-Pacific was the second-largest region in the global animal vaccines market. The regions covered in the global veterinary vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global veterinary vaccines market is segmented - 1) By Application: Livestock Vaccines, Companion Animal Vaccines 2) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others 3) By Disease Type: Anaplasmosis, Canine Parvovirus, Foot and Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive and Respiratory Syndrome (PRRS)

The companion animal veterinary vaccines market consists of sales of companion animal vaccines by entities (organizations, sole traders, and partnerships) that manufacture companion animal vaccines. Companion animal vaccines are substances that are used to stimulate the production of antibodies and provide immunity against one or several diseases in pets such as dogs, birds, and cats. Only goods and services traded between entities or sold to end consumers are included. The main products of companion animal veterinary vaccines are inactivated, live attenuated, recombinant, and other products. A recombinant vaccine is one that was created using recombinant DNA technology. This entails inserting DNA encoding an antigen (such as a bacterial surface protein) that triggers an immunological response into bacterial or mammalian cells, expressing the antigen in these cells, and then purifying it from them. The products are administered through oral, parenteral, and other routes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies and drug stores, and other distribution channels. The global companion animal veterinary vaccines market size is expected to grow from $3.05 billion in 2021 to $3.25 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%. The global companion animal veterinary vaccine market size is expected to grow to $4.19 billion in 2026 at a CAGR of 6.6%. Increased pet ownership by Gen X and Gen Y adults contributed to the growth of the companion animal veterinary vaccines market during the historic period. According to the APPA, millennials, or Gen Y represents the largest segment of pet owners for all types of pets. More than 80% of Gen Y and Gen Z own a dog and 50% or less own a cat as a pet. Multiple pet ownership is also on the rise in some parts of the world. According to the 2019-2020 APPA National Pet Owners Survey, 67% of US households own pets, which is equal to 84.9 million homes. Pet owners are well aware of advanced facilities and are willing to spend a large amount of money on the health of their pets. Therefore, the rise in pet ownership aids in the growth of the companion animal veterinary vaccines market. The high cost of veterinary vaccines is expected to restrain the growth of the market. According to data from Harris Interactive, in the USA, households with pets spent about $1,000 in pet care. There are around 70% of households in the USA who own a pet and only 39% have enough in their savings to cover high spending related to pet care. According to a report by PET IQ in 2019, in the USA, nearly 28% of households experienced barriers to veterinary care in the past two years. 80% of pet owners are unable to obtain preventative care due to financial constraints. There are several instances when it happens that the pet owners cannot afford expensive animal treatment and this factor restrained the growth of the companion animal veterinary vaccines market. Usually, the average cost of the rabies vaccine varies typically from about $1,200 to $6,500. Thus, the high costs for companion animal veterinary vaccines will restrain the growth of the market over the forecast period. Companies in the companion animal veterinary vaccine industry are increasingly collaborating and partnering with other players to drive product innovations. To succeed in the increasingly competitive veterinary market, companion animal veterinary vaccines companies are entering into new geographies and developing innovative products through sharing skills and expertise with other players. For instance, Merck & Co.’s subsidiary MSD Animal Health announced a strategic partnership with Vinovo B.V., a division of Viscon Hatchery Automation, the leading hatchery automation company, to provide a new standard in safe and effective Vinovo vaccination to improve bird welfare and reduce vaccine reactions. In June 2019, Zoetis collaborated with a multidisciplinary team of public and private partners spanning animal and human health. In April 2019, Merck Animal Health, a US-based company that is involved in manufacturing, fabricating, or processing of drugs for human or veterinary use, acquired Antelliq Corporation for about $2.4 billion. Through this acquisition, Merck Animal Health aims to implement animal health digital tracking, traceability, and monitoring technology and complement the existing portfolio of vaccines and pharmaceuticals. Antelliq Corporation is an animal intelligence group that provides devices for animal identification, monitoring, and traceability. Major players in the companion animal veterinary vaccines market are Boehringer Ingelheim, Eli Lilly and Company (Elcano), Heska Co., Merck Animal Health, Virbac, Zoetis, ElancoCeva Sante Animal S.A., Bayer Healthcare, NEOGEN CORPORATION, and ImmuCell Corporation. North America was the largest region in the companion animal veterinary vaccines market in 2021. Asia-Pacific was the second-largest region in the global companion animal vaccines market. The regions covered in the global companion animal veterinary vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the companion animal veterinary vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global companion animal veterinary vaccines market is segmented - 1) By Product: Inactivated, Live Attenuated, Recombinant, Others 2) By Route of Administration: Oral, Parenteral, Others 3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies and Drug Stores, Others

The cancer biologics market consists of sales of cancer biologics. Cancer biologic drugs are the products that are produced from living organisms or contain components of a living organisms. Biologic drugs include a wide variety of products which are derived from human, animal or microorganisms by using biotechnology. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancers, others and distributed through various channels such as hospitals, clinics, others. The global cancer biologics market size is expected to grow from $76.46 billion in 2021 to $86.64 billion in 2022 at a compound annual growth rate (CAGR) of 13.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer biologics market is expected to reach $129.05 billion in 2026 at a CAGR of 10.5%. Rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market growth. Chronic disorders are the diseases which persists over a long period of time and hinder the health of people with disabilities and cancer is one of the common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to World Health Organization (WHO), in 2020 chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion as they are proteins which are quickly digested and inactivated if given by mouth so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers which help the physicians to decide the treatments for their patients by utilizing physiological biomarkers for predicting the performance. Predictive biomarkers study tumor growth in patients by analyzing the major etiological factors as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the cost-effective treatment regimens, especially for the biologics based on gene therapy. According to FDA approval process of new cancer treatment and biological products, the application for the approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from a number of alternative sources. In May 2019, Evotec SE, drug discovery and development solutions provider acquired Just Biotherapeutics, Inc. for $90 million. The acquisition will help Evotec's business to grow into offering the biologics into the therapeutic areas such as oncology. Just Biotherapeutics is a US-based unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for development and manufacturing of biologics at highest standards. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis and Pfizer. North America was the largest region in the cancer biologics market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Others 2) By Application: Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Others 3) By Distribution Channel: Hospitals, Clinics, Others

The drugs for immunotherapy market consist of sales of immunotherapy drugs. Immunotherapy drugs help the immune system to fight cancer by stimulating the immune system of the body and generate an immune response aiding the production of antibodies. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune & inflammatory diseases, infectious diseases, others and is used by various sectors such as hospitals and clinics, ambulatory surgical centers, others. The global drugs for immunotherapy market size is expected to grow from $186.39 billion in 2021 to $208.56 billion in 2022 at a compound annual growth rate (CAGR) of 11.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The immunotherapy drugs market is expected to reach $310.48 billion in 2026 at a CAGR of 10.5%. The immunotherapy drugs market is being driven by rising incidences of cancer globally. The major causes for most cancers include obesity, smoking, alcohol, improper eating habits. According to the American Cancer Society, in 2019, around 606,880 deaths were caused in USA due to prevalence of the cancer. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving market growth. The high cost of immunotherapy drugs is acting as a restraint on the drugs for immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as drugs are made specifically for each patient and investment costs in the research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes it unaffordable, thereby affecting market growth. Manufacturers of immunotherapy drugs are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of immunotherapy drugs are governed by various regulatory bodies such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson and UbiVac. North America was the largest region in the immunotherapy market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Others 2) By Therapy Area: Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, Others 3) By End-User: Hospitals and Clinics, Ambulatory Surgical Centers, Others

The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment. Cancer treatment vaccines, also called therapeutic vaccines are a type of immunotherapy, which stops tumor growth, destroys cancer cells and prevents the reoccurrence of cancers. The market consists of revenue generated by the company’s manufacturing cancer vaccines by the sales of these products. The main types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Therapeutic vaccinations aid in the recognition of a virus or malignant cell by the immune system. The different types of cancers include prostate, cervical, colorectal, throat, others and involves various technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vector & DNA cancer vaccines. The several sectors include cancer treatment centers, research institutes. The global cancer vaccines market size is expected to grow from $4.47 billion in 2021 to $5.29 billion in 2022 at a compound annual growth rate (CAGR) of 18.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer vaccine market is expected to reach $9.36 billion in 2026 at a CAGR of 15.3%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer vaccines market during the forecast period. According to the American Cancer Society, there were 1,7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer vaccines market over the coming years. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of cancer vaccines manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, which is affecting the cancer vaccine sales. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. This trend is expected to continue during the forecast period and limit the demand for cancer vaccines. Companies in the cancer vaccines market are increasingly investing in preventive or prophylactic vaccines for cancer prevention. Prophylactic vaccines are designed to build immunity in a patient. A prophylactic or preventative vaccine involves introducing antigens into a person's body. According to the World Health Organization, cervical cancer was reported as the second-most common cancer in women with an estimation of 84% new cases worldwide. So far, there are 3 HPV vaccines currently present for the prophylaxis of cancers. Two among these will protect against both HPV 16 and HPV 18, which causes 70% of cervical cancer and the third vaccine prevents 3 more oncogenic HPV types, which further causes 20% of cervical cancers. These three vaccines include Gardasil and Gardasil9 by Merck and Cervarix by GSK. In April 2019, Bayer, through its investment arm Leaps by Bayer, has invested in a US-based biotechnology firm Khloris Biosciences, which is focused on developing prophylactic anti-cancer vaccines. In May 2020, Merck, a US-based pharmaceutical company, acquired Themis Bioscience for an undisclosed amount. The acquisition is expected to complement Merck's capabilities in the development, manufacturing, and distribution of vaccines. Themis Bioscience is a pharmaceutical company that manufactures vaccines and immune-modulatory therapies developed using the measles virus vector platform based on a vector originally. Major players in the cancer vaccines market are GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi Pasteur, Sanpower Group and CSL Limited. The regions covered in the cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer vaccines market is segmented - 1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines 2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines 3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Others 4) By End-User: Cancer Treatment Centers, Research Institutes

The DTP vaccines market consists of sales of vaccines used for the treatment of diphtheria, tetanus, and pertussis (whooping cough) and related services by entities (organizations, sole traders and partnerships) that produce vaccines for diphtheria, tetanus, and pertussis (whooping cough). The different types of vaccines available for these diseases include DTaP (diphtheria, tetanus, and acellular pertussis) vaccine, DT (diphtheria and tetanus) vaccine, Tdap (combined tetanus, diphtheria and acellular pertussis) vaccine and TD (tetanus and diphtheria) vaccine. The market consists of revenue generated by the companies manufacturing DTP vaccines by the sales of these products. The main types of products in DTP vaccines are DTaP, TD and Tdap. The diphtheria, tetanus, and whooping cough (DTaP) vaccine helps children under the age of seven build protection to three lethal bacteria-borne diseases: diphtheria, tetanus, and whooping cough (pertussis). The different types of diseases include diphtheria, pertussis, tetanus and involves various sectors such as hospitals, clinics, vaccination centers. The global DTP vaccines market size is expected to grow from $4.00 billion in 2021 to $4.45 billion in 2022 at a compound annual growth rate (CAGR) of 11.0%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The DTP vaccine market is expected to reach $5.79 billion in 2026 at a CAGR of 6.8%. Governments across the world are encouraging the R&D of DTP vaccines to disallow the spread of the diseases. Countries such as India have the Universal Immunisation Programme that aims to provide recommended vaccines against tuberculosis, polio and other diseases including diphtheria, tetanus and whooping cough for all Indian children. The country regularly conducts vaccination drives, which is expected to positively impact the growth of the market. These initiatives are expected to drive the growth of the market in the forecast period. The inadequate access to vaccines in under-developed countries is expected to limit the growth of the DTP vaccines global market. According to the World Health Organization’s global estimates, around 19.4 million infants did not had access to DTP vaccines and around 60% of these children live in under-developed and developing countries. Countries such as the Central African Republic, Chad, Equatorial Guinea, Guinea, Samoa, Somalia, South Sudan, Syrian Arab Republic, and Ukraine have less than 50% coverage of DTP vaccination. Lack of access to vaccines in under-developed countries is expected to hamper the market growth. Companies in the DTP vaccines market are increasingly investing in manufacturing DTP combination vaccines, which reduces multiple vaccination shots for immunization against infectious disease. DTP combination vaccines such as tetravalent (DTP-HepB), pentavalent (DTP-HepB-Hib) and hexavalent vaccine (DTP-Hib-HepB-IPV) are available to provide the same protection as individual vaccine shots given separately. In May 2020, Merck acquired Thermis, a company focused on vaccines and immuno-modulation therapies for infectious diseases, for an undisclosed amount. Thermis is involved in the discovery, development and production of vaccines with a sophisticated and versatile technology platform. Merck is expected to leverage the vaccine technology enhanced by Thermis and the company will become a fully-owned subsidiary of Merck after completion of this deal. Major players in the DTP vaccines market are Merck & Co, Sanofi, GSK, Lanzhou Institute of Biological Products, Novartis AG, Pfizer Inc, Johnson & Johnson, Seqirus, AJ Vaccines, and Bionet-Asia. The regions covered in the DTP vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the DTP vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global DTP vaccines market is segmented - 1) By Product Type: DTaP, TD, Tdap 2) By Disease: Diphtheria, Pertussis, Tetanus. 3) By End-User: Hospitals, Clinics, Vaccination Centers

The pediatric vaccines market consists of sales of pediatric vaccines and its related services used to provide immunity to infants and children for specific diseases. The pediatric vaccine is a preparation of killed microorganisms, living attenuated organisms, or living fully virulent organisms that are administered to stimulate the production of antibodies and provide immunity against one or several diseases among children. Pediatric vaccines are used in childhood immunization schedules to enhance a child’s immunity or prevent diseases such as diphtheria, tetanus, pertussis, influenza, Hepatitis B, polio, and many other infectious and non-infectious diseases. The main types of pediatric vaccines are monovalent and multivalent. A monovalent vaccine is made up of only one antigen strain. The technology used include live attenuated, inactivated, toxoid, conjugate and other technologies to provide immunity from infectious disease, allergy and cancer. The global pediatric vaccine market size is expected to grow from $31.44 billion in 2021 to $36.64 billion in 2022 at a compound annual growth rate (CAGR) of 16.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pediatric vaccine market is expected to reach $57.51 billion in 2026 at a CAGR of 11.9%. The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. According to the World Health Organization, chronic disease prevalence irose by 57% in the year 2020. The increased prevalence of chronic diseases among children rises the demand for immunization from chronic diseases, hence, driving the pediatric vaccines market’s growth. Vaccine refusal by parents for their children is a prevailing tradition in many countries. Among the reasons for withholding children for vaccination are lack of knowledge, religious and philosophical objections, exaggerated concerns regarding vaccine safety, and others. According to a nationwide survey found that over half (51%) of pediatric services in the United States have the policy to dismiss families that refuse childhood vaccines. 37% of pediatricians themselves said they often dismissed families for refusing vaccines, and 6% said they would dismiss a family for choosing to reach out to crucial early vaccines. Governments are imposing laws and organizing awareness programs to overcome parent’s and family’s resistance to the child’s vaccine, but are unable to impose any strict rules against parents’ refusal for children’s immunization, which may hinder the pediatric vaccines market’s growth. The demand for novel vaccines is steadily growing to deliver improved immunization against challenging infectious diseases (e.g. tuberculosis, HIV/ AIDS) and non-communicable chronic diseases such as cancer and neurodegenerative diseases. Novel approaches to vaccine development include structural immunogenic design, gene-based vaccine platforms, and effective adjuvant recombinant antigen formulations. To meet the increasing demand for novel vaccines, there is a continuous quest for pediatric vaccine manufacturers and developers for innovation of vaccine design and manufacturing technologies. For instance, in January 2020, Hilleman laboratories, global research, and development organization, has announced their plans to develop a novel vaccine against Group B Streptococcus, a major cause for neonatal infections in women, in the area of maternal and child health. Major players in the pediatric vaccines market are GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Indian Immunologicals Limited, AstraZeneca plc, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., Zydus Cadila, BIO-MED, Squibb, Novartis, Abbott Laboratries, Eli Lillyand Company, F. Hoffmann- La Roche Ltd., Novo Nordisk A/S, VF Corporation, Sinovac Biotech Ltd., Bristol- Myers, Sun Pharmaceutical Industries Ltd, Sellas and Takeda Pharmaceutical Company Limited, Daiichi Sankyo, Bristol- Myers and Sinovac Biotec Ltd. North America was the largest region in the pediatric vaccines market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pediatric vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global pediatric vaccine market is segmented - 1) By Vaccine Type: Monovalent, Multivalent 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies 3) By Application: Infectious Disease, Allergy, Cancer

Pharmaceutical Drugs And Biologics Logistics Market Definition